Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/ 35 fiber

Cancer Gene Therapy

Volumn 11, Issue 3, 2004, Pages 227-236

  Slager, Elisabeth H ^a   Van Der Minne, Caroline E ^a   Goudsmit, Jaap ^b   Van Oers, Johanna M M ^a   Kostense, Stefan ^b   Havenga, Menzo J E ^b   Osanto, Susanne ^a   Griffioen, Marieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Dendritic cells; Immunotherapy; Melanoma; Recombinant adenovirus; T lymphocytes

Indexed keywords

ADENOVIRUS VECTOR; CD8 ANTIGEN; GENE PRODUCT; HLA A ANTIGEN; PROTEIN CAMEL; PROTEIN NY ESO ORF2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; DENDRITIC CELL; GENE TRANSFER; HLA SYSTEM; MELANOMA; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INDUCTION; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; CYSTEINE ENDOPEPTIDASES; DENDRITIC CELLS; EPITOPE MAPPING; GENE THERAPY; GENETIC VECTORS; HLA-A ANTIGENS; HLA-B7 ANTIGEN; HUMANS; INTERLEUKINS; MEMBRANE PROTEINS; MULTIENZYME COMPLEXES; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS;

ADENOVIRIDAE; ANIMALIA; CAMELIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 1442324395     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700674     Document Type: Article

References (47)

1. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85-100.
2. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997;3:37-44.
3. Jager E, Bernhard H, Romero P, et al. Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer. 1996;66:162-169.
4. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
6. Slingluff Jr CL, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024.
7. Lau R, Wang F, Jeffery G, et al. Phase 1 trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother. 2001;24:66-78.
8. Scheibenbogen C, Schadendorf D, Bechrakis NE, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer. 2003;104:188-194.
9. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA. 1995;92:8078-8082.
10. Hu X, Chakraborty NG, Sporn JR, et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56:2479-2483.
11. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219-230.
12. Thurner B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
13. Gnjatic S, Jager E, Chen W, et al. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA. 2002;99:11813-11818.
14. Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003;170:2161-2169.
15. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc-Natl Acad Sci USA. 2002;99:16168-16173.
16. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphoeytes against major histocompatibility complex class 11 negative tumors. J Exp Med. 1998;187:693-702.
17. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
18. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
19. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
20. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998;161:5607-5613.
21. + T cells in patients with melanoma. J Immunol. 2000;164:3402-3412.
22. Ribas A, Butterfield LH, McBride WH, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 1997;57:2865-2869.
23. Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol. 1999;163:699-707.
24. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
25. Segerman A, Mei YF, Wadell G. Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J Virol. 2000;74:1457-1467.
26. Rea D, Havenga MJ, van den Assem M, et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol. 2001;166:5236-5244.
27. Havenga MJ, Lemckert AA, Ophorst OJ, et al. Exploiting the natural diversity in adenovirus tropisin for therapy and prevention of disease. J Virol. 2002;76:4612-4620.
28. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy. 1999;6:1574-1583.
29. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase 1 clinical trial for localized mesothelioma. Hum Gene Ther. 1998;9:2121-2133.
30. Gahery-Segard H, Farace F, Godfrin D, et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol. 1998;72:2388-2397.
31. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol. 1988;62:2321-2328.
32. Flomenberg PR, Chen M, Munk G, et al. Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. J Infect Dis. 1987;155:1127-1134.
33. Aarnoudse CA, van den Doel PB, Heemskerk B, et al. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999;82:442-448.
34. Lethe B, Lucas S, Michaux L, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer. 1998;76:903-908.
35. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914-1918.
36. Rimoldi D, Rubio-Godoy V, Dutoit V, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol. 2000;165:7253-7261.
37. Wang RF, Johnston SL, Zeng G, et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998;161:3598-3606.
38. Slager EH, Borghi M, van der Minne CE, et al. CD4(+) Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003;170:1490-1497.
39. Havenga MJ, Lemckert AA, Grimbergen JM, et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol. 2001;75:3335-3342.
40. Shabram PW, Giroux DD, Goudreau AM, et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther. 1997;8:453-465.
41. He TC, Zhou S, da-Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
42. Griffioen M, Borghi M, Schrier PI, et al. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer. 2001;93:549-555.
43. Gnjatic S, Atanackovic D, Matsuo M, et al. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol. 2003;170:1191-1196.
44. Eberl G, Renggli J, Men Y, et al. Extracellular processing and presentation of a 69-mer synthetic polypetide to MHC class I-restricted T cells. Mol Immunol. 1999;36:103-112.
45. Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000;165:6047-6055.
46. Tuettenberg A, Jonuleit H, Tuting T, et al. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8(+) T cells: implications for an efficient vaccination strategy. Gene Therapy. 2003;10:243-250.
47. Kuball J, Schuler M, Antunes FE. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Therapy. 2002;9:833-843.